Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.0%. By the end of trading, Regeneron Pharmaceuticals rose $3.98 (1.5%) to $274.00 on average volume. Throughout the day, 666,851 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 784,100 shares. The stock ranged in a price between $269.00-$277.11 after having opened the day at $269.53 as compared to the previous trading day's close of $270.02. Other companies within the Drugs industry that increased today were: CytRx Corporation ( CYTR), up 52.2%, Genvec ( GNVC), up 31.0%, MediciNova ( MNOV), up 22.2% and Idera Pharmaceuticals ( IDRA), up 19.8%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $27.0 billion and is part of the health care sector. The company has a P/E ratio of 38.8, above the S&P 500 P/E ratio of 17.7. Shares are up 57.8% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share.

On the negative front, ImmunoCellular Therapeutics ( IMUC), down 59.6%, Prima Biomed ( PBMD), down 12.3%, Compugen ( CGEN), down 10.0% and Rexahn Pharmaceuticals ( RNN), down 9.4% , were all laggards within the drugs industry with Novartis ( NVS) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

What Angela Merkel's Uncertain Political Future Means for Greece's Debt Woes

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern

Goldman Is Bullish on Oil, Sees Demand Outweighing Inventory Concern